[1] Rajput, R., Ved, J., Reverse causality in Empa-Reg Outcome: the proverbial elephant?. Diabetes Res Clin Pract 127 (2017), 288–289.
[2] Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
[3] Flegal, K.M., Graubard, B.I., Williamson, D.F., Cooper, R.S., Reverse causation and illness-related weight loss in observational studies of body weight and mortality. Am J Epidemiol 173 (2011), 1–9.
[4] Verdecchia, P., Reboldi, G., Angeli, F., Trimarco, B., Mancia, G., Pogue, J., et al. Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease. Hypertension 65 (2015), 108–114.
[5] van Walraven, C., Davis, D., Forster, A.J., Wells, G.A., Time-dependent bias was common in survival analyses published in leading clinical journals. J Clin Epidemiol 57 (2004), 672–682.
